Join Growin Stock Community!

Mineralys therapeutics, inc.MLYS.US Overview

US StockHealthcare
(No presentation for MLYS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MLYS AI Insights

MLYS Overall Performance

MLYS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MLYS Recent Performance

-2.49%

Mineralys therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

MLYS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MLYS Key Information

MLYS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MLYS Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Price of MLYS

MLYS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MLYS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.02
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.02
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is MLYS's latest earnings report released?

    The most recent financial report for Mineralys therapeutics, inc. (MLYS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MLYS's short-term business performance and financial health. For the latest updates on MLYS's earnings releases, visit this page regularly.

  • How much cash does MLYS have?

    At the end of the period, Mineralys therapeutics, inc. (MLYS) held Total Cash and Cash Equivalents of 217.6M, accounting for 0.36 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MLYS's EPS continuing to grow?

    According to the past four quarterly reports, Mineralys therapeutics, inc. (MLYS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.52. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MLYS?

    Mineralys therapeutics, inc. (MLYS)'s Free Cash Flow (FCF) for the period is -28.87M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 42.51% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.